HCPLive
2014 American Thoracic Society International Conference

2014 American Thoracic Society International Conference | ATS 2014

The 2014 American Thoracic Society International Conference in San Diego "will offer the latest information on clinical, basic and translational science in pulmonary, critical care and sleep medicine."

Conference Coverages

Monotherapy with N-acetylcysteine No Better Than Placebo for Preserving Lung Function in Patients with Idiopathic Pulmonary Fibrosis
Monotherapy with N-acetylcysteine No Better Than Placebo for Preserving Lung Function in Patients with Idiopathic Pulmonary Fibrosis
Study results showed treatment with N-acetylcysteine did not slow the decline in lung function, reduce acute exacerbations, or improve survival compared with placebo in patients with idiopathic pulmonary fibrosis.
Nintedanib Treatment Slows Disease Progression in Patients with Idiopathic Pulmonary Fibrosis
Results from two studies show that treatment with the novel kinase inhibitor nintedanib significantly slowed disease progression in patients with idiopathic pulmonary fibrosis (IPF). However, only one study showed nintedanib had any effect on slowing deterioration in quality of life or reducing the risk of a first acute exacerbation compared with placebo.
Pirfenidone Improves Survival in Idiopathic Pulmonary Fibrosis
Recently published study results, when combined with results from previous clinical trials, show treatment with the antifibrotic drug pirfenidone slows disease progression and improves survival in patients with idiopathic pulmonary fibrosis (IPF). These findings, if they lead the FDA to reevaluate and approve this drug, could be a game changer for patients with IPF, a disease marked by a high mortality rate and few treatment options.
Treatment with Dual Bronchodilator Produces Significant Improvements in Lung Function in Patients with COPD
Combination treatment with a fixed dose of indacaterol and glycopyrronium bromide was associated with significant improvements in several measures of lung function and health status compared to placebo and tiotropium in treatment-naïve patients with COPD.
Combination Treatment with Umeclidinium Plus Vilanterol Produces Significant Improvements in Lung Function in Patients with COPD
Subgroup analysis from four studies reveals treatment with a once-daily, fixed-dose combination of umeclidinium vilanterol improves lung function at 24 weeks for a broad range of patients with moderate to severe COPD.
AUGMENT Study Results Show Combination Therapy Superior to Monotherapy for COPD
Treatment with a fixed-dose combination of aclidinium 400 µg and formoterol 12 µg significantly improved bronchodilation in patients with moderate to severe COPD compared with aclidinium or formoterol monotherapy alone.
Rosuvastatin Treatment Does Not Improve Lung Function in Patients with COPD
Study results presented at the 2014 American Thoracic Society International Conference show that treatment with rosuvastatin reduces markers of inflammation in patients with COPD after 12 weeks, but is not associated with improvements in measures of lung function.
Simvastatin Does Not Affect Exacerbation Rates in High-Risk Patients with COPD
Study results presented at the 2014 American Thoracic Society International Conference show that treatment with simvastatin did not decrease exacerbation rates or time to first exacerbation in patients with COPD.
Study of TLR-9 Agonist for Treatment of Allergic Asthma Discontinued after Disappointing Results
Researchers reported no treatment effects after 12 weeks in a population of patients with persistent moderate to severe allergic asthma.

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$